Guohui Wan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/81691/publications.pdf

Version: 2024-02-01

35 papers

2,662 citations

279487
23
h-index

395343 33 g-index

37 all docs

 $\begin{array}{c} 37 \\ \text{docs citations} \end{array}$

37 times ranked

4411 citing authors

#	Article	IF	Citations
1	RNA N6-methyladenosine demethylase FTO promotes breast tumor progression through inhibiting BNIP3. Molecular Cancer, 2019, 18, 46.	7.9	416
2	<scp>RNA</scp> m ⁶ A methylation regulates sorafenib resistance in liver cancer through <scp>FOXO</scp> 3â€mediated autophagy. EMBO Journal, 2020, 39, e103181.	3.5	271
3	The ATM Kinase Induces MicroRNA Biogenesis in the DNA Damage Response. Molecular Cell, 2011, 41, 371-383.	4.5	208
4	TP53 loss creates therapeutic vulnerability inÂcolorectal cancer. Nature, 2015, 520, 697-701.	13.7	192
5	Long non-coding RNA ANRIL (CDKN2B-AS) is induced by the ATM-E2F1 signaling pathway. Cellular Signalling, 2013, 25, 1086-1095.	1.7	180
6	Oncogenic Wip1 Phosphatase Is Inhibited by miR-16 in the DNA Damage Signaling Pathway. Cancer Research, 2010, 70, 7176-7186.	0.4	159
7	miRâ€203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase. Molecular Oncology, 2014, 8, 83-92.	2.1	156
8	miRNA response to DNA damage. Trends in Biochemical Sciences, 2011, 36, 478-484.	3.7	154
9	A novel non-coding RNA lncRNA-JADE connects DNA damage signalling to histone H4 acetylation. EMBO Journal, 2013, 32, 2833-2847.	3.5	120
10	Amplification of USP13 drives ovarian cancer metabolism. Nature Communications, 2016, 7, 13525.	5. 8	99
11	The RNA-Binding Protein DDX1 Promotes Primary MicroRNA Maturation and Inhibits Ovarian Tumor Progression. Cell Reports, 2014, 8, 1447-1460.	2.9	86
12	RNA-binding protein RALY reprogrammes mitochondrial metabolism via mediating miRNA processing in colorectal cancer. Gut, 2021, 70, 1698-1712.	6.1	63
13	DNA-Damage-Induced Nuclear Export of Precursor MicroRNAs Is Regulated by the ATM-AKT Pathway. Cell Reports, 2013, 3, 2100-2112.	2.9	58
14	N6-Methyladenosine modification: a novel pharmacological target for anti-cancer drug development. Acta Pharmaceutica Sinica B, 2018, 8, 833-843.	5.7	58
15	Lossâ€ofâ€Function Genetic Screening Identifies Aldolase A as an Essential Driver for Liver Cancer Cell Growth Under Hypoxia. Hepatology, 2021, 74, 1461-1479.	3.6	53
16	Tumorâ€essociated macrophages in immunotherapy. FEBS Journal, 2021, 288, 6174-6186.	2.2	48
17	Noncoding RNAs in DNA Repair and Genome Integrity. Antioxidants and Redox Signaling, 2014, 20, 655-677.	2.5	44
18	eEF-2 kinase is a critical regulator of Warburg effect through controlling PP2A-A synthesis. Oncogene, 2016, 35, 6293-6308.	2.6	36

#	Article	IF	CITATIONS
19	New Strategy for COVID-19: An Evolutionary Role for RGD Motif in SARS-CoV-2 and Potential Inhibitors for Virus Infection. Frontiers in Pharmacology, 2020, 11, 912.	1.6	36
20	A study of somatolactin actions by ectopic expression in transgenic zebrafish larvae. Journal of Molecular Endocrinology, 2010, 45, 301-315.	1.1	33
21	miR-137 regulates epithelial-mesenchymal transition in gastrointestinal stromal tumor. Tumor Biology, 2014, 35, 9131-9138.	0.8	32
22	Nodal Facilitates Differentiation of Fibroblasts to Cancer-Associated Fibroblasts that Support Tumor Growth in Melanoma and Colorectal Cancer. Cells, 2019, 8, 538.	1.8	30
23	Crosstalk between the DNA damage response pathway and microRNAs. Cellular and Molecular Life Sciences, 2012, 69, 2895-2906.	2.4	26
24	Differential regulation of zebrafish metallothionein-II (zMT-II) gene transcription in ZFL and SJD cell lines by metal ions. Aquatic Toxicology, 2009, 91, 33-43.	1.9	16
25	Protein phosphatase 1 inhibits p53 signaling by dephosphorylating and stabilizing Mdmx. Cellular Signalling, 2013, 25, 796-804.	1.7	15
26	Methyladenosine Modification in RNAs: Classification and Roles in Gastrointestinal Cancers. Frontiers in Oncology, 2020, 10, 586789.	1.3	14
27	Degradation of intracellular TGF- \hat{l}^21 by PROTACs efficiently reverses M2 macrophage induced malignant pathological events. Chemical Communications, 2020, 56, 2881-2884.	2.2	13
28	Design and Discovery of Natural Cyclopeptide Skeleton Based Programmed Death Ligand 1 Inhibitor as Immune Modulator for Cancer Therapy. Journal of Medicinal Chemistry, 2020, 63, 11286-11301.	2.9	12
29	AP-1 confers resistance to anti-cancer therapy by activating XIAP. Oncotarget, 2018, 9, 14124-14137.	0.8	12
30	Discovery and Structural Optimization of Toddacoumalone Derivatives as Novel PDE4 Inhibitors for the Topical Treatment of Psoriasis. Journal of Medicinal Chemistry, 2022, 65, 4238-4254.	2.9	10
31	FOXO3 mutation predicting gefitinib-induced hepatotoxicity in NSCLC patients through regulation of autophagy. Acta Pharmaceutica Sinica B, 2022, 12, 3639-3649.	5.7	4
32	Measurement of Circulating Tumor Cells to Track Hepatocellular Carcinoma Progression After Liver Transplantation-Case Report. Frontiers in Oncology, 2021, 11, 760765.	1.3	2
33	Identification of 2-Benzylidene-tetralone Derivatives as Highly Potent and Reversible Firefly Luciferase Inhibitors. ACS Medicinal Chemistry Letters, 2022, 13, 304-311.	1.3	1
34	Mechanism of aberrant long non-coding RNA expression in an adriamycin-resistant liver cancer cell strain. Digestive and Liver Disease, 2020, 52, 582-587.	0.4	0
35	RNA and RNA derivatives: light and dark sides in cancer immunotherapy. Antioxidants and Redox Signaling, 2022, , .	2.5	0